A randomized, double-blind study examining the comparative efficacies and safety of inhaled epinephrine and nasal decongestant in hospitalized infants with acute bronchiolitis

Pediatr Infect Dis J. 2010 Jan;29(1):71-3. doi: 10.1097/INF.0b013e3181b0602e.

Abstract

Optimal treatment of acute bronchiolitis is currently unclear. In a double-blind study, we found no significant differences between inhaled epinephrine and nasal decongestant in hospitalized infants with acute bronchiolitis regarding length of hospitalization, need for oxygen supplementation, or intravenous fluids and clinical score. Nasal decongestant is as effective as inhaled epinephrine in acute bronchiolitis.

Trial registration: ClinicalTrials.gov NCT00622817.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Bronchiolitis / drug therapy*
  • Bronchodilator Agents / administration & dosage*
  • Bronchodilator Agents / adverse effects*
  • Bronchodilator Agents / therapeutic use
  • Double-Blind Method
  • Epinephrine / administration & dosage*
  • Epinephrine / adverse effects*
  • Epinephrine / therapeutic use
  • Female
  • Fluid Therapy / statistics & numerical data
  • Humans
  • Infant
  • Inpatients
  • Length of Stay / statistics & numerical data
  • Male
  • Nasal Decongestants / administration & dosage*
  • Nasal Decongestants / adverse effects*
  • Nasal Decongestants / therapeutic use
  • Oxygen Inhalation Therapy / statistics & numerical data
  • Severity of Illness Index

Substances

  • Bronchodilator Agents
  • Nasal Decongestants
  • Epinephrine

Associated data

  • ClinicalTrials.gov/NCT00622817